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Fifty-five years after publication of the first hematopoietic stem cell transplantation this technique has become an
accepted treatment option for defined hematologic and non-hematologic disorders. There is considerable interest
in understanding differences in its use and trends on a global level and the macro-economic factors associated with
these differences. Data on the numbers of hematopoietic stem cell transplants performed in the 3-year period
2006-2008 were obtained from Worldwide Network for Blood and Marrow Transplantation member registries
and from transplant centers in countries without registries. Population and macro-economic data were collected
from the World Bank and from the International Monetary Fund. Transplant rates were analyzed by indication,
donor type, country, and World Health Organization regional offices areas and related to selected health care indi-
cators using single and multiple linear regression analyses. Data from a total of 146,808 patients were reported by
1,411 teams from 72 countries over five continents. The annual number of transplants increased worldwide with
the highest relative increase in the Asia Pacific region. Transplant rates increased preferentially in high income
countries (P=0.02), not in low or medium income countries. Allogeneic transplants increased for myelodysplasia,
chronic lymphocytic leukemia, acute leukemias, and non-malignant diseases but decreased for chronic myeloge-
nous leukemia. Autologous transplants increased for autoimmune and lymphoproliferative diseases but decreased
for leukemias and solid tumors. Transplant rates (P<0.01), donor type (P<0.01) aand disease indications (P<0.01)
differed significantly between countries and regions. Transplant rates were associated with Gross National
Income/capita (P<0.01) but showed a wide variation of explanatory content by donor type, disease indication and
World Health Organization region. Hematopoietic stem cell transplantation activity is increasing worldwide. The
preferential increase in high income countries, the widening gap between low and high income countries and the
significant regional differences suggest that different strategies are required in individual countries to foster
hematopoietic stem cell transplantation as an efficient and cost-effective treatment modality. 
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ABSTRACT
Introduction 
Quantitative differences in rates of hematopoietic stem cell
transplantation (HSCT) have been well described in the
recent past: more patients are transplanted in countries with
a higher national income. HSCT requires a specific infrastruc-
ture, depends on a network of specialists and remains associ-
ated with significant morbidity and mortality; it is a prime
example of costly, specialized medicine. Broader use of
HSCT has therefore long been limited to high income coun-
tries.1,2 This has changed over the last decade, for several rea-
sons. Transplantation of autologous or allogeneic bone mar-
row, peripheral blood or cord blood stem cells has become
the treatment of choice for many patients with defined
severe congenital or acquired disorders of the hematopoietic
system. Registers of unrelated donors have expanded to
include more than 20 million human leukocyte antigen
(HLA)-typed volunteer donors worldwide and increased the
likelihood of finding a suitable matched donor. Results have
improved, including those for elderly patients and for those
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with co-morbid conditions. As a consequence, novel indi-
cations are being explored and transplant numbers have
increased worldwide.3-9
Furthermore, the World Health Organization (WHO)
has recognized transplantation as an important global
task. Transplantation of cells, tissues and organs has
extended the lifespan of hundreds of thousands of patients
worldwide and enhanced their quality of life; it has
become standard of care for many patients with single
organ failure and should no longer be restricted to affluent
countries or individuals. The guiding principles of the
WHO declare regulation of transplantation on a national
level as a governmental responsibility. Regulation includes
harmonized data collection on use and outcome as an
essential tool to improve results and to achieve efficient
and cost-effective use of resources.10,11 Information on use
and trends is therefore a prime prerequisite for any health
care agency. The Worldwide Network for Blood and
Marrow Transplantation (WBMT), an umbrella organiza-
tion of HSCT and a non-governmental organization recog-
nized by WHO, has taken on the task of facilitating HSCT.
It previously identified availability of resources, govern-
mental support and access of patients to the therapy as
key factors associated with quantitative differences in
transplant rates.12 It now presents an in-depth assessment
of factors associated with qualitative differences in use and
trends on a global level.
Design and Methods
Study design
This retrospective survey followed the principles of the WBMT
through data collection by its network of international or regional
member organizations.12 The main outcome measures were the
assessment of transplant rates by indication and donor type for
each country, the changes over the 3-year period from 2006 to
2008 and their associations with defined macro-economic factors.
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Table 1. Population description of patients with HSCT by WHO regional offices area from 2006 to 2008.
East Mediterranean/ Africa SE Asia/ Americas Europe Total
Western Pacific
N. % N. % N. % N. % N. %
Donor type*
Allogeneic  HSCT 2509 63 15547 60 19463 46 28707 39 66226 45
Family donor 2474 99 7944 51 10034 52 14523 51 34975 53
Unrelated donor 35 1 7603 49 9429 48 14184 49 31251 47
Autologous  HSCT 1477 37 10384 40 23007 54 45714 61 80582 55
Total ** 3986 3 25931 18 42470 29 74421 50 146808 100
Main indications allogeneic*
Leukemias 1455 58 12126 78 13620 70 20476 71 47677 72
Acute leukemia 1059 73 9585 79 9619 71 14271 70 34534 72
Chronic leukemia 276 19 1086 9 1827 13 2259 11 5448 11
MDS/MPS 120 8 1455 12 2174 16 3946 19 7695 16
Lymphoproliferative disorders 99 4 1463 9 3414 18 4868 17 9844 15
Lymphoma 68 69 1280 87 2729 80 3347 69 7424 75
Plasma cell disorders 31 31 183 13 685 20 1521 31 2420 25
Non-malignant disorders 928 37 1747 11 2192 11 2954 10 7821 12
Bone marrow failure 468 50 1094 63 1247 57 1359 46 4168 53
Other non-malignant 460 50 653 37 945 43 1595 54 3653 47
Solid tumors 3 0 132 1 65 0.3 199 1 399 0.6
Other 24 1 79 1 172 1 210 1 485 1
Main indications autologous*
Lymphoproliferative disorders 1213 82 8156 79 20023 87 37999 83 67391 84
Lymphoma 734 61 4279 52 9719 49 18994 50 33726 50
Plasma cell disorders 479 39 3877 48 10304 51 19005 50 33665 50
Solid tumors 101 7 1347 13 1951 8 4260 9 7659 9
Leukemias 153 10 717 7 852 4 2926 6 4648 6
Acute leukemia 129 84 694 97 816 96 2453 84 4092 88
Chronic leukemia 10 7 14 2 22 3 353 12 399 9
MDS/MPS 14 9 9 1 14 2 120 4 157 3
Non malignant disorders 10 1 88 1 154 1 453 1 705 1
Bone marrow failure 0 0 0 0 1 1 3 1 4 0.5
Other non-malignant 10 100 88 100 153 99 450 99.3 701 99
Other 0 0 76 1 27 0.1 76 0.1 179 0.2
*Column percentages; **row percentages; MDS/MPS, myelodysplastic syndrome/myeloproliferative syndrome.
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Data collection and validation
Data were obtained from 1,411 teams in 72 countries over five
continents on the numbers of HSCT performed in the years 2006,
2007 and 2008 by indication and donor type (Table 1). Data were
reported via the mandatory worldwide compatible reporting sys-
tem of initial transplant data (ABMTRR, CBMTG, and CIBMTR)
or by a separate survey data form (APBMT, EBMT, EMBMT, and
SBTMO).9,13-16
Data were pooled, validated through confirmation by the
reporting team, which received a computer printout of the entered
data, by selective comparison with MED-A data sets in the EBMT
ProMISE data system or by cross-checking with National
Registries. Double reporting was excluded. Onsite visits of select-
ed teams are part of the quality control program within CIBMTR
and EBMT teams.
Definitions 
Transplant rates 
Transplant rates were computed as the number of patients treat-
ed with a first HSCT per 10 million inhabitants.2 Patients with a
re-transplant or a second or third HSCT were not included. 
Population data and data on Gross National Income (GNI)/capi-
ta, health care expenditures/capita, governmental health care
expenditure, and World Bank Category (by GNI/capita) were
obtained from the World Bank (www.worldbank.org) and from the
International Monetary Fund (www.imf.org). 
World Health Organization regional offices areas
The allocation of individual countries to a region followed the
WHO regional offices classification (www.who.int/about/regions/en/)
and the previously reported restriction to four regions:11 (i) the
Americas; (ii) Asia; (iii) Eastern-Mediterranean and Africa; and (iv)
Europe (Figure 1). 
Statistical analysis
The association of macro-economic factors with HSCT rates
and the changes from 2006 to 2008 were estimated by single and
multiple linear regression analyses using the least squares method.
The significance of relationships was measured using τ statistics; a
level of 5% was considered statistically significant. The goodness
of fit was calculated using the coefficient of determination (R2), the
square of Pearson’s correlation coefficient. For single and multiple
regression analyses, the dependent variables were transformed to
be closer to an underlying linear model. For the multiple regression
analyses, all factors were assessed for their multicollinearity.
The t test was used to evaluate significant differences between
the WHO regions. All statistical analyses were performed with
EViews version 5.1 (Quantitative Micro Software, Irvine, CA,
USA).
Results 
Numbers of hematopoietic stem cell transplants 
for the years 2006-2008, indications, donor type 
and stem cell source
During the 3-year period considered, 146,808 patients
underwent a first HSCT (45% allogeneic and 55% autolo-
gous) (Table 1). The analysis showed substantial hetero-
A. Gratwohl et al.
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Figure 1. Transplant rates for the total number of HSCT in participating countries by WHO regional offices
area for the years 2006-2008. Regions are colored by WHO regional offices area code (see text). Shades of
colors reflect transplant rates (numbers of HSCT, allogeneic and autologous combined, by 10 million inhabi-
tants).
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geneity in indication and donor type by WHO region. The
main indications were lymphoproliferative disorders
(53%) and leukemias (36%), followed by solid tumors
(5%) and non-malignant disorders and others (6%). There
was, however, a distinctly different pattern for allogeneic
and autologous HSCT. The main indications for allogeneic
HSCT were leukemias (72%), lymphoproliferative disor-
ders (15%) and non-malignant disorders (12%), while the
main indications for autologous HSCT were  lymphopro-
liferative disorders (84%), solid tumors (9%) and non-
malignant disorders (1%) (Table 1).
Information on stem cell source was available for a total
of 142,822 patients. Peripheral blood was used predomi-
nantly in related and unrelated HSCT (64%) and in autol-
ogous HSCT (98%). Bone marrow remained an important
source for allogeneic HSCT (26%), specifically for non-
malignant disorders (56%); its use was minimal for autol-
ogous HSCT (2%). Allogeneic HSCT (in patients for
whom information on stem cell source was available)
were performed from family donors in 51% of cases (43%
matched, 7% mismatched/haploidentical, 0.5% twins and
0.43% cord blood) and from unrelated donors in 49%. Of
the 49% unrelated HSCT, 54% were obtained from
peripheral blood, 27% from bone marrow and 19% from
cord blood.
The highest number of HSCT was reported from
Europe (51% of which 39% allogeneic HSCT) followed
by the Americas (29%; 46% allogeneic HSCT), Asia (18%;
60% allogeneic HSCT) and Eastern Mediterranean/Africa
(3%; 63% allogeneic HSCT) as shown in Table 1. The dis-
tribution was asymmetric concerning the proportion of
autologous and allogeneic HSCT with the pattern in
America and Europe being significantly different from that
in Asia and Eastern Mediterranean/Africa (P<0.05) and
concerning the repartition of main indications with a high-
er proportion of non-malignant indications in the Eastern
Mediterranean/Africa region (P<0.01) and a higher propor-
tion of acute leukemia in Asia (P<0.01). This asymmetric
distribution was primarily influenced by the World Bank
category of the participating countries (Figure 2). Low
income countries preferentially used allogeneic HSCT
compared to autologous HSCT, low and middle income
countries preferentially used family donors compared to
unrelated donors and showed a higher proportion of non-
malignant indications. 
Transplant rates 
Over the 3-year period studied, the average absolute
number of HSCT in the participating countries ranged
from 1 (Philippines) to 11,228 (USA) (Figure 1). The trans-
plant rate ranged from 0.1 to 732 per 10 million inhabi-
tants (median 119) for total HSCT, from 0 to 397 (median
49) for allogeneic HSCT and from 0 to 412 (median 81) for
autologous HSCT. There were no autologous or allogeneic
transplants in countries with fewer than 300,000 inhabi-
tants or with a GNI/capita below $US 690; there were no
Worldwide use and trends of HSCT
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Figure 2. Indications and donor types of 146,808 HSCT by World Bank category in the years 2006-2008. The figure reflects the relative pro-
portions of allogeneic (blue) or autologous (red) HSCT (left three columns), of allogeneic donor type [family donor (green) or unrelated donor
(blue)] (central left three columns), main indications for allogeneic HSCT (central right three columns), and main indications for autologous
HSCT (right three columns; for color code see figure) by low, middle of high income according to World Bank category. For definitions see the
Design and Methods section. NM: non-malignant disorders; ST: solid tumors; LPD: lymphoproliferative disorders; Leuk: leukemia.
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unrelated donor transplants in countries with a GNI/capita
below $US 850. 
Transplant rates were significantly associated with com-
mon health care indicators, lnGNI/capita (R2 = 61%)
(Figure 3), health care expenditure/capita (R2 = 64%) or
governmental health care expenditure/capita (R2 = 63%)
(data not shown). These associations were similar for 2006,
2007 and 2008. They differed significantly for donor
types, indications and by the WHO regions.
The association was stronger and with a greater
explanatory content for autologous HSCT (R2 = 55%) than
for allogeneic HSCT (R2 = 49%) as shown for lnGNI/capi-
ta (Figure 3A). Explanatory content was higher for unrelat-
ed donor than for family donor HSCT. It was highest for
acute leukemia (R2 = 49%), lower for non-malignant disor-
ders (R2 =15%) (Figure 3B) and non-existent for non-malig-
nant disorders with HSCT from family donors (R2 = 4%). 
Unrelated donor transplant rates were also associated
with lnGNI/capita (R² = 48%), with the presence of an
unrelated donor registry in the respective country
(R2=30%) and the number of donors in the respective
donor registry ( R2=15%). The combined effect of these
three factors in a multiple regression reached even R2
=59%. If only countries performing unrelated donor trans-
plants were included in the analysis, the explanatory con-
tent reached R2 =72% (Figure 3C). Unrelated cord blood
transplant rates were weakly associated with lnGNI/capi-
ta (R2 = 24%) and with the presence of a cord blood bank
in the respective country (R2=10%). The 264 family donor
cord blood transplants were minimally associated
(lnGNI/capita: R2 =5%). The three factors lnGNI/capita,
presence of an unrelated donor registry and the number of
donors in the respective donor registry also exerted a com-
bined effect on total transplant rates (R2=63%; all regions
combined) but to a different extent in the different
regions. Associations with lnGNI/capita were strongest in
the Americas (R2=94%), followed by Asia (R2=67%),
Europe (R2=57%) and the Eastern Mediterranean/Africa
region (R2=25%).
Trends from 2006 to 2008 
The numbers of HSCT increased from 46,563 in 2006 to
51,536 in 2008 (+10%). The increase in reporting teams
from 1,327 in 2006 to 1,407 in 2008 (+6%) was one rea-
A. Gratwohl et al.
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Figure 3. Transplant rates and Gross National Income per capita (GNI/cap). (A) Transplant rates for allogeneic and autologous HSCT by WHO
regional offices area, donor type and GNI/cap. Symbols reflect transplant rates (TR; numbers of HSCT by 10 million inhabitants) in partici-
pating countries and the respective lnGNI/cap. Colors indicate WHO region (see Figure 1); squares indicate allogeneic HSCT, triangles autol-
ogous HSCT. Vertical lines separate countries by World Bank (WB) category. (B) Transplant rates for allogeneic HSCT for acute leukemia and
non-malignant disorders by WHO regional offices areas and GNI/cap. Symbols reflect transplant rates (TR; numbers of HSCT by 10 million
inhabitants) in participating countries and the respective lnGNI/cap. Colors indicate WHO regional offices areas (see Figure 1); squares indi-
cate acute leukemia, triangles non-malignant disorders. Vertical lines separate countries by World Bank category. (C) Unrelated donor trans-
plant rates by WHO regional offices areas, GNI/cap and presence of an unrelated donor registry. Symbols represent transplant rates; open
symbols indicate absence of an unrelated donor registry, full symbols the presence of such a registry and size of symbols numbers of its
registered donors. Colors indicate WHO region (see Figure 1). Only countries with unrelated donor HSCT are included. (D) Change in trans-
plant rates (all transplants) from 2006 to 2008 by GNI/cap and WHO regional offices areas. Symbols represent increase or decrease in trans-
plant rates (TR) from 2006 to 2008; colors indicate WHO regional offices areas (see figure 1).
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son, but even more was the increase of the median num-
ber of transplants/year (+26.3%) performed at each center
[38 (range 3-180), to 46 (3-421) and 48 (1-389) in 2006,
2007 and 2008, respectively]. Changes differed between
regions as well as for main indications, donor types and
stem cell sources (Figure 4). 
The relative increase was greater for related and unrelat-
ed allogeneic HSCT (+17%) than for autologous HSCT (+
5%; Figure 4A). The greatest increase in absolute and rel-
ative numbers was observed in the Asia/Western Pacific
region (+39%; Figure 4B) for both allogeneic (+50%) and
autologous (+22%) HSCT, followed by Europe (+6%
overall; allogeneic +10%, autologous +3%), the Americas
(+4% overall; allogeneic +9%, autologous +1%, and the
Eastern Mediterranean/Africa (+19) for allogeneic (+11%)
and autologous (+34%) HSCT. The relative increase in
HSCT numbers was higher in low income countries
(Figure 4C) but not in absolute numbers or in transplant
rates (see below). The increase in HSCT numbers was pre-
dominantly accounted for by unrelated donor HSCT for
patients with leukemia in America and Europe, and by
family donor HSCT for patients with non-malignant dis-
orders in Asia and the Eastern Mediterranean /Africa. 
The numbers of autologous HSCT increased for lym-
phoproliferative disorders (+8%) and decreased for
leukemia (-15%) and solid tumors (-2%) as shown in
Figure 4D. The numbers of allogeneic HSCT increased for
leukemia (+20%) and non-malignant disorders (+26%;
Figure 4E) with divergent trends for myelodysplasia
(+26%), acute myeloid leukemia (+23%), acute lym-
phoblastic leukemia (+27%) and chronic lymphocytic
lymphocytic (+24.6%), which all increased, compared to
chronic myeloid leukemia (-17%), for which fewer allo-
geneic HSCT were performed. The numbers of allogeneic
HSCT increased for bone marrow failure syndromes
(+21%) and other non-malignant disorders (+27%).
Changes in use of stem cell source are shown in Figure 4F
with the highest relative but not absolute increase in cord
blood HSCT. The relatively higher increase in transplant
numbers in countries with lower incomes (R2 = 11%) did
Worldwide use and trends of HSCT
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Figure 4. Total HSCT in 2006
and relative increase or
decrease (in %) in 2007 and
2008 according to (A) donor
type, (B) WHO region, (C) World
Bank Category (high, medium
and low income by GNI/capita),
(D) autologous transplant indi-
cation, (E) allogeneic transplant
indication and (F) allogeneic
stem cell source
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not translate into a greater increase in transplant rates. In
contrast transplant rates were weakly but positively asso-
ciated with lnGNI/capita (R2 = 3%) (Figure 3D). Linear
trend analysis confirmed this with there being a positive
and increasing linear trend (P=0.02, total HSCT) for the
absolute number of HSCT in high income countries but
none for the middle (P=0.57) and low (P=0.35) income
countries. The trend was most clearly underpinned for
unrelated donor HSCT for acute leukemia in high income
countries (P=0.004). There was no association of increase
or decrease in transplant rates with change in lnGNI/capi-
ta over time (R2 = 1%).
Discussion
This global analysis shows that availability of resources
has quantitative and qualitative impacts on the use of
HSCT. Transplant rates are higher in high income coun-
tries but the difference is not the same for all indications
or all donor types. High income countries use autologous
and allogeneic HSCT for more indications. They are more
likely to use autologous than allogeneic HSCT and unre-
lated donors than family donors. Transplant rates for
autologous HSCT are more likely to be influenced by
GNI/capita, as illustrated by the higher explanatory con-
tent for autologous HSCT. In contrast, countries with lim-
ited resources preferentially restrict the use of HSCT to
allogeneic transplants with stem cells from family donors
for non-malignant indications or chronic leukemia. The
previously described differences between the WHO
regional offices areas11 might, therefore, reflect differences
in resources rather than in opinions. It is comforting to
observe the continued increase in transplant numbers in
low income countries, but it remains a concern that trans-
plant rates increased to a greater extent in high income
than in middle or low income countries and the gap
between the countries is widening. 
Transplant rates were associated with GNI/capita for all
indications and all donor types but with vast differences in
explanatory content and impact. How can these findings
be interpreted? A high explanatory content with a strong
impact can be considered as a situation with increasing
demand without saturation: more patients with acute
leukemia will be transplanted in the coming years if the
necessary resources, money and donors can be made
available. A low explanatory content with a weak impact
indicates a different situation. Transplant rates are no
longer driven by a higher national income alone. Factors
other than availability of resources must come into play.
One factor could be related to different beliefs of the med-
ical community on the value of a given therapy in different
countries. However, the focus on transplantation from
matched family donors for non-malignant disorders and
chronic leukemia in lower income countries is suggestive
of prioritization in a cost-effectiveness approach. HSCT
might be less expensive and equally effective as lifelong
treatment with supportive care or expensive drugs in
selected patients. There is no need for intensive high cost
pre-treatment as is the case for patients with acute
leukemia and, the search for a matched family donor
requires minimal resources.17-21
The economic aspects of HSCT with its patient-centered
approach have traditionally concentrated on costs of the
individual procedure for an individual patient.17,22-24 Studies
on macro-economic aspects or on cost-effectiveness in
individual countries have gained broader acceptance only
recently.11,21,22,25 They were triggered in part by some rapid
changes in the use of HSCT, such as for breast cancer or
chronic myeloid leukemia18,26 and by the rising awareness
of the disturbing gap between unlimited requests and lim-
ited resources in any health care system.27,28 Availability of
resources, governmental support and access to therapy
were identified as factors associated with use; availability
of resources, evidence, external regulations and positive or
negative expectations of transplant physicians as factors
associated with diffusion.11,25 These previous findings and
the observations in this report form an objective basis for
recommendations or guidelines by professional organiza-
tions. They point to the different requirements within high
or low income countries, hence different cost-effectiveness
considerations.20,21,26-28 Unrelated donor transplant rates
were associated with GNI/capita, the presence of an unre-
lated donor registry and the number of registered donors.
The association is likely reciprocal; high income countries
perform more HSCT in general and are more likely to
invest in an unrelated donor registry. Competent authori-
ties will have to balance the advantages and costs of estab-
lishing and maintaining a national donor registry with its
own local HLA-haplotype distribution with alternative
strategies.24,29,30 The even representation of unrelated HSCT
in high income countries documents the functioning
worldwide exchange of graft material.   
Some caveats remain. Data for this survey were collect-
ed for the years 2006 to 2008. Patterns might have
changed since; differences in indications might reflect dif-
ferent disease prevalences or missing information. Some
congenital non-malignant disorders such as immune defi-
ciency syndromes or hemoglobinopathies are highly pres-
ent in some countries and absent in others.31,32 Evidently, a
few teams known to have performed HSCT did choose
not to report.13 Data reporting is mandatory by law in
some countries, limited to allogeneic HSCT in other coun-
tries and not required in other countries. The discrepancy
between performed and reported HSCT might be higher
for autologous HSCT than for allogeneic HSCT.9,14-16 There
is, however, no indication for a systematic bias and more
recent data from the European survey are consistent with
a widening gap.13
This report gives no information on outcome. Such a
report would require additional time and another frame-
work. Outcome is influenced by many factors, including
the disease, the pre-treatment, characteristics of the
patients and donors, transplant techniques, the transplant
team, its quality management system and the income of
the country in which the transplants take place.3,5,33-36
Combined analyses on use and outcome are needed to
ascertain that those patients with the highest need and the
best likelihood of benefiting from a transplant procedure
are selected within a given country. Transplant organiza-
tions and competent authorities worldwide are currently
challenged to implement the WHO guiding principles.
The present data provide a platform to begin with. They
indicate that one size will not fit all. Regulatory aspects
and recommendations on therapy should not only be
transparent and consistent but should also be well targeted
according to specific cost-effectiveness considerations and
needs in the individual countries.36,37
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